Biotech company Pharming Group NV announces the analyst report completed by Joseph Pantginis, Ph.D. from Roth Capital Partners is published.

Pharming reported financial results for 2014, posting EPS of €(0.014) vs. our estimate of €(0.01) and revenues of €21.3 million vs. our estimate of €28.6 million. Royalties from first sales of Ruconest in the U.S. contributed €0.3 million. Pharming ended the year with €34.4 million in cash.

  • Click Here For Full Report in HTML

Visit our Analyst Coverage & Reports page to read more reports by ROTH Capital Partners.

Contact

Sijmen de Vries, CEO: T: +31 (0)71 524 7400

"This update is for informational purposes only and is not viewed by Pharming to be of a price sensitive nature"

distributed by